iRhythm lifts 2026 revenue outlook to $890m–$895m alongside VitalConnect closing

iRhythm Holdings now expects 2026 revenue of $890m to $895m, after reporting third-quarter sales of $221.6m on 5 November. The materials available do not state the previous guidance range or a year-earlier comparison, so the size of the upgrade cannot be gauged here.

The quarter was still loss-making on a GAAP basis, with a net loss of $29.9m. On an adjusted EBITDA basis, which strips out items the company excludes, iRhythm reported a profit of $51.2m.

On 5 October, iRhythm finished buying VitalConnect, bringing a second FDA-cleared cardiac monitor into the Zio family. The product is a mobile cardiac telemetry device. The material does not give the price or say how much VitalConnect contributes to the guidance.

On the financing side, iRhythm closed a $300m senior secured revolving credit facility on 3 November, two days before the results. Pricing, maturity and covenants were not provided.

The company has also filed 510(k) applications with the FDA for paediatric use of Zio Monitor. A 510(k) asks the agency to agree that a device is substantially equivalent to one already legally on the market. Submission dates and the age groups covered were not disclosed, and no decision has been reported.